top of page

Representative publications:

  1. Cheng Wang#, Yumei Chen#, Yun Nan Hou, Qiufang Liu , Di Zhang , Haitao Zhao , You Zhang , Shuxian An, Lianghua Li, Jian Hou , Gang Huang, Jianjun Liu*, Yong Juan Zhao*, Weijun Wei*. ImmunoPET imaging of multiple myeloma with [68Ga]Ga-NOTA-Nb1053. European Journal of Nuclear Medicine and Molecular Imaging. 2021 Aug;48(9):2749-2760.

  2. Wei W#, Jiang D#, Lee HJ, Li M, Kutyreff CJ, Engle JW, Liu J*, Cai W*. Development and characterization of CD54-targeted immunoPET imaging in solid tumors. European Journal of Nuclear Medicine and Molecular Imaging. 2020;47(12):2765-2775.

  3. Wei W#, Liu Q#, Jiang D, Zhao H, Kutyreff CJ, Engle JW, Liu J*, Cai W*. Tissue Factor-Targeted ImmunoPET Imaging and Radioimmunotherapy of Anaplastic Thyroid Cancer. Advanced Science. 2020;7(13):1903595.

  4. Wei W#, Jiang D#, Ehlerding EB, Barnhart TE, Yang Y, Engle JW, Luo QY*, Huang P*, Cai W*. CD146-Targeted Multimodal Image-Guided Photoimmunotherapy of Melanoma. Advanced Science. 2019;6(9):1801237.

  5. Wei W, Rosenkrans ZT, Liu J, Huang G*, Luo Q-Y*, Cai W*. ImmunoPET: Concept, Design, and Applications. Chemical Reviews. 2020;120(8):3787-3851.

  6. Shuxian An, Di Zhang , You Zhang, Cheng Wang, Liang Shi, Weijun Wei, Gang Huang, Jianjun Liu. GPC3-targeted immunoPET imaging of hepatocellular carcinomas. European Journal of Nuclear Medicine and Molecular Imaging. 2022 Jul;49(8):2682-2692.

  7. Wei W*,#, Zhang D#, Wang C, Zhang Y, An S, Chen Y, Huang G, Liu J*. Annotating CD38 Expression in Multiple Myeloma with [18F]F-Nb1053. Molecular Pharmaceutics. 2021 Nov 30. doi: 10.1021/acs.molpharmaceut.1c00733. Online ahead of print.

  8. Wei W*,#, Zhang Y#, Zhang D, Liu Q, An S, Chen Y, Huang G, Liu J*. Annotating BCMA Expression in Multiple Myelomas. Molecular Pharmaceutics. 2021 Nov 29. doi: 10.1021/acs.molpharmaceut.1c00628. Online ahead of print.

  9. Wei W, Younis MH, Lan X, Liu J, Cai W. Single-Domain Antibody Theranostics on the Horizon. J Nucl Med. 2022 Oct;63(10):1475-1479.

Publication list:

  1. Liang, C., Huang, W., Zhang, Y., Zhang, D., An, S., Wu, Q., Zhao, H., Wang, C., Huang, G., Wei, W., & Liu, J. (2023). ImmunoPET Imaging of CD47 with VHH-Derived Tracers in Pancreatic Cancers. Molecular pharmaceutics, 20(8), 4184–4195. 

  2. Zhang D, Huang G, Liu J, Wei W*. Claudin18.2-targeted cancer theranostics. Am J Nucl Med Mol Imaging. 2023 Apr 25;13(2):64-69.

  3. Zhang Y, Zhang D, An S, Liu Q, Liang C, Li J, Liu P, Wu C, Huang G*, Wei W*, Liu J*. Development and Characterization of Nanobody-Derived CD47 Theranostic Pairs in Solid Tumors. Research (Wash D C). 2023;6:0077.

  4. Wu Q, Yang S, Liu J, Jiang D, Wei W*. Antibody theranostics in precision medicine. Med. 2023 Feb 10;4(2):69-74.

  5. Wei W*, Jiang D, Evangelista L, Cai W. Antibody-Based Imaging and Therapy for Precision Medicine. Mol Pharm. 2022 Oct 3;19(10):3453-3455.

  6. Wei W*. Voices in Molecular Pharmaceutics: Meet Dr. Weijun Wei Who Is Developing Theranostic Nuclear Medicine Agents for Clinical Use. Mol Pharm. 2022 Oct 3;19(10):3456.

  7. Xie F, Wei W*. [64Cu]Cu-ATSM: an emerging theranostic agent for cancer and neuroinflammation. Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):3964-3972.

  8. An S, Huang G, Liu J, Wei W*. PSMA-targeted theranostics of solid tumors: applications beyond prostate cancers. Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):3973-3976.

  9. Wei W, Younis MH, Lan X, Liu J, Cai W. Single-Domain Antibody Theranostics on the Horizon. J Nucl Med. 2022 Oct;63(10):1475-1479.

  10. Wang Q, Zhang X, Wei W*, Cao M*. PET Imaging of Lung Cancers in Precision Medicine: Current Landscape and Future Perspective. Mol Pharm. 2022 Oct 3;19(10):3471-3483.

  11. Wu Q, Huang G, Wei W*, Liu J*. Molecular Imaging of Renal Cell Carcinoma in Precision Medicine. Mol Pharm. 2022 Oct 3;19(10):3457-3470.

  12. Yang E, Liu Q, Huang G, Liu J, Wei W*. Engineering nanobodies for next-generation molecular imaging. Drug Discov Today. 2022 Jun;27(6):1622-1638.

  13. An S, Zhang D, Zhang Y, Wang C, Shi L, Wei W*, Huang G*, Liu J*. GPC3-targeted immunoPET imaging of hepatocellular carcinomas. Eur J Nucl Med Mol Imaging. 2022 Jul;49(8):2682-2692.

  14. Wei W, Zhang D, Wang C, Zhang Y, An S, Chen Y, Huang G, Liu J. Annotating CD38 Expression in Multiple Myeloma with [18F]F-Nb1053. Mol Pharm. 2022 Oct 3;19(10):3502-3510.

  15. Wei W, Zhang Y, Zhang D, Liu Q, An S, Chen Y, Huang G, Liu J. Annotating BCMA Expression in Multiple Myelomas. Mol Pharm. 2022 Oct 3;19(10):3492-3501.

  16. Dun Y, Huang G, Liu J, Wei W. ImmunoPET imaging of hematological malignancies: From preclinical promise to clinical reality. Drug Discov Today. 2022 Apr;27(4):1196-1203.

  17. Wei W, Chen Y, Zhao X, Liu J. Myofibrosarcoma infiltrating pulmonary arteries diagnosed on 18F-FDG PET/CT. Cao M. Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1429-1430.

  18. Wei W*, Huang G, Liu J. Advancing the diagnosis of epithelioid hemangioendothelioma by 18F-FDG PET/CT. Am J Nucl Med Mol Imaging. 2021 Jun 15;11(3):230-232.

  19. Jin Y#, Liu B#, Younis MH, Huang G, Liu J, Cai W*, Wei W*. Next-Generation Molecular Imaging of Thyroid Cancer. Cancers (Basel). 2021 Jun 25;13(13):3188.

  20. Cheng Wang#, Yumei Chen#, Yun Nan Hou, Qiufang Liu , Di Zhang , Haitao Zhao , You Zhang , Shuxian An, Lianghua Li, Jian Hou , Gang Huang, Jianjun Liu*, Yong Juan Zhao*, Weijun Wei*. ImmunoPET imaging of multiple myeloma with [68Ga]Ga-NOTA-Nb1053. Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2749-2760.

  21. Wei W#, Jiang D#, Lee HJ, Li M, Kutyreff CJ, Engle JW, Liu J*, Cai W*. Development and characterization of CD54-targeted immunoPET imaging in solid tumors. European Journal of Nuclear Medicine and Molecular Imaging. 2020;47(12):2765-2775.

  22. Wei W#, Liu Q#, Jiang D, Zhao H, Kutyreff CJ, Engle JW, Liu J*, Cai W*. Tissue Factor-Targeted ImmunoPET Imaging and Radioimmunotherapy of Anaplastic Thyroid Cancer. Advanced Science. 2020;7(13):1903595.

  23. Wei W, Rosenkrans ZT, Liu J, Huang G*, Luo Q-Y*, Cai W*. ImmunoPET: Concept, Design, and Applications. Chemical Reviews. 2020;120(8):3787-3851. (IF= 52.758)

  24. Weijun Wei, Dawei Jiang , Hye Jin Lee , Jonathan W Engle , Hisaya Akiba , Jianjun Liu , Weibo Cai. ImmunoPET Imaging of TIM-3 in Murine Melanoma Models. Adv Ther (Weinh). 2020 Jul;3(7):2000018.

  25. Miao Li#, Weijun Wei#, Todd E Barnhart, Dawei Jiang, Tianye Cao, Kevin Fan, Jonathan W Engle, Jianjun Liu, Weiyu Chen, Weibo Cai. ImmunoPET/NIRF/Cerenkov multimodality imaging of ICAM-1 in pancreatic ductal adenocarcinoma. Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2737-2748.

  26. Wei W#, Jiang D#, Ehlerding EB, Barnhart TE, Yang Y, Engle JW, Luo QY*, Huang P*, Cai W*. CD146-Targeted Multimodal Image-Guided Photoimmunotherapy of Melanoma. Advanced Science. 2019;6(9):1801237.

  27. Wei W, Jiang D, Rosenkrans ZT, Barnhart TE, Engle JW, Luo Q, Cai W. HER2-targeted multimodal imaging of anaplastic thyroid cancer. American Journal of Cancer Research. 2019;9(11):2413-2427.

  28. Wei W, Hardin H, Luo QY. Targeting Autophagy in Thyroid Cancers. Endocr Relat Cancer. 2019;26(4):R181-R194.

  29. Wei WJ#, Sun ZK#, Shen CT, Song HJ, Zhang XY, Qiu ZL*, Luo QY*. Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer. Theranostics. 2017; 7(4):987-1001.

  30. Wei W#, Ehlerding EB#, Lan X*, Luo Q*, Cai W*. PET and SPECT imaging of melanoma: the state of the art. Eur J Nucl Med Mol Imaging. 2018; 45(1):132-150.

  31. Wei W#, Ehlerding EB#, Lan X*, Luo Q*, Cai W*. Molecular imaging of β-cells: diabetes and beyond. Adv. Drug Delivery Rev. 2019;139:16-31.

  32. Wei WJ*, Zhang GQ*, Luo QY. Postsurgical Management of Differentiated Thyroid Cancer in China. Trends Endocrinol Metab. 2018;29(2):71-73.

  33. Wei W#, Jiang D#, Ehlerding EB, Luo Q*, Cai W*. Noninvasive PET Imaging of T cells. Trends in Cancer. 2018. 4(5):359-373.

  34. Wei W#, Ni D#, Ehlerding EB, Luo QY*, Cai W*. PET imaging of receptor tyrosine kinases in cancer. Mol Cancer Ther. 2018;17(8):1625-1636.

  35. Wei W, Rosenkrans ZT, Luo QY#, Lan X#, Cai W#. Exploiting Nanomaterial-mediated Autophagy for Cancer Therapy. Small Methods. 2018, 1800365. DOI: 10.1002/smtd.201800365.

  36. Wei WJ#, Shen CT#, Song HJ, Qiu ZL*, Luo QY*. Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib. Oncol. Rep. 2016; 36 (3):1576-84.（IF=2.976）

  37. Wei WJ#, Shen CT#, Song HJ, Qiu ZL*, Luo QY*. MicroRNAs as a potential tool in the differential diagnosis of thyroid cancer: a systematic review and meta-analysis. Clin Endocrinol. 2016; 84(1):127-33.

  38. Wei WJ, Shen CT, Song HJ, Qiu ZL, Luo QY*. Metastatic malignant fibrous histiocytoma infiltrating sigmoid colon: A Case diagnosed with the help of 18F-FDG PET/CT. Clin Nucl Med. 2016; 41(4):338-40.

  39. Wei WJ, Sun ZK, Shen CT, Qiu ZL, Luo QY*. Adefovir-Induced Hypophosphatemic Osteomalacia Mimicking Bone Metastases From Primary Hepatocarcinoma. Clin Nucl Med. 2017; 42(9):e405-e406.

  40. Wei WJ#, Shen CT#, Song HJ, Qiu ZL*, Luo QY*. Comparison of SPET/CT, SPET and planar imaging using 99mTc-MIBI as independent techniques to support minimally invasive parathyroidectomy in primary hyperparathyroidism: A meta-analysis. Hell J Nucl Med. 2015; 18 (2):127-35.

  41. Wei WJ*, Sun ZK*, Shen CT, Zhang XY, Tang J, Song HJ, Qiu ZL, Luo QY. Value of 99mTc-MDP SPECT/CT and 18F-FDG PET/CT scanning in the evaluation of malignantly transformed fibrous dysplasia. Am J Nucl Med Mol Imaging. 2017; 7(3):92-104. ESCI

  42. Zhang GQ#, Wei WJ#, Song HJ, Sun ZK, Shen CT, Zhang XY, Chen XY, Qiu ZL*, Luo QY*. Programmed cell death-ligand 1 overexpression in thyroid cancer. Accepted. Endocrine Practice. 2019;25(3):279-286.

  43. Shen CT#, Wei WJ#, Song HJ, Qiu ZL, Luo QY*. Value of post-therapeutic 131I scintigraphy in stimulated serum thyroglobulin-negative patients with metastatic differentiated thyroid carcinoma. Endocrine. 2016; 51 (2): 283-90.

  44. Shen CT#, Wei WJ#, Song HJ, Qiu ZL, Luo QY*. Afamin promotes glucose metabolism in papillary thyroid carcinoma. Mol Cell Endocrinol. 2016; 434: 108-15.

  45. Shen CT#, Wei WJ#, Qiu ZL, Song HJ, Zhang XY, Sun ZK, Luo QY*. Metformin reduces glycometabolism of papillary thyroid carcinoma in vitro and in vivo. J Mol Endocrinol. 2017; 58 (1):15-23.

  46. Qiu ZL#, Wei WJ#, Sun ZK, Shen CT, Song HJ, Zhang XY, Zhang GQ, Chen XY, Luo QY*. Circulating Tumor Cells Correlate with Clinicopathological Features and Outcomes in Differentiated Thyroid Cancer. Cell Physiol Biochem. 2018; 48(2):718-730.

  47. Qiu ZL#, Wei WJ#, Shen CT, Song HJ, Zhang XY, Sun ZK, Luo QY*. Diagnostic Performance of 18F-FDG PET/CT in Papillary Thyroid Carcinoma with Negative 131I-WBS at first Postablation, Negative Tg and Progressively Increased TgAb Level. Sci Rep. 2017; 7(1):2849.

  48. Hye Jin Lee, Emily B Ehlerding , Dawei Jiang, Todd E Barnhart, Tianye Cao, Weijun Wei, Carolina A Ferreira, Peng Huang, Jonathan W Engle, Weibo Cai. Dual-labeled Pertuzumab for Multimodality Image-Guided Ovarian Tumor Resection. Am J Cancer Res, 9 (7), 1454-1468.

  49. Ni D, Ferreira CA, Barnhart TE, Quach V, Yu B, Jiang D, Wei W, Liu H, Engle JW, Hu P, Cai W. Magnetic Targeting of Nanotheranostics Enhances Cerenkov Radiation-Induced Photodynamic Therapy. J Am Chem Soc. 2018. 7; 140(44):14971-14979.

  50. Qiu ZL, Shen CT, Sun ZK, Wei WJ, Zhang XY, Song HJ, Luo QY. Circulating Long Non-Coding RNAs Act as Biomarkers for Predicting 131I Uptake and Mortality in Papillary Thyroid Cancer Patients with Lung Metastases. Cell Physiol Biochem. 2016; 40(6):1377-1390.

  51. Zhang XY, Song HJ, Qiu ZL, Shen CT, Chen XY, Sun ZK, Wei WJ, Zhang GQ, Luo QY. Pulmonary metastases in children and adolescents with papillary thyroid cancer in China: prognostic factors and outcomes from treatment with 131I. Endocrine. 2018. doi: 10.1007/s12020-018-1678-1.

  52. Shen CT, Zhang XY, Qiu ZL, Sun ZK, Wei WJ, Song HJ, Luo QY. Thyroid autoimmune antibodies in patients with papillary thyroid carcinoma: a double-edged sword? Endocrine. 2017; 58(1):176-183.

  53. Shen CT, Zhang Y, Liu YM, Yin S, Zhang XY, Wei WJ, Sun ZK, Song HJ, Qiu ZL, Wang CR, Luo QY. A distinct serum metabolic signature of distant metastatic papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2017; 87(6):844-852.

  54. Shen CT, Qiu ZL, Song HJ, Wei WJ, Luo QY. miRNA-106a directly targeting RARB associates with the expression of Na(+)/I(-) symporter in thyroid cancer by regulating MAPK signaling pathway. J Exp Clin Cancer Res. 2016; 35 (1):101.

  55. Song HJ, Qiu ZL, Shen CT, Wei WJ, Luo QY. Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors. Eur J Endocrinol. 2015; 173 (3):399-408.

  56. Qiu ZL, Shen CT, Song HJ, Wei WJ, Luo QY. Differential expression profiling of circulation microRNAs in PTC patients with non-131I and 131I-avid lungs metastases: a pilot study. Nucl Med Biol. 2015; 42 (5):499-504.

bottom of page